RCUS:NYSE, Arcus Biosciences, Inc.
RCUS stock overview
Arcus Biosciences, Inc. (RCUS:NYSE) closed at $17.43 on November 13, 2026,
down 1.91% on the day.
The stock trades 45.1% below its 52-week high of $31.74
and 2.3% above its 52-week low of $17.03.
Over the past year, it lost 13.2%.
Arcus Biosciences, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $17.43
- Day change
- -1.91%
- Volume
- 1,138,753
- Average volume
- 1,846,765
- Market cap
- 2B+
- 52-week range
- $17.03 – $31.74
- 50-day average
- $22.87
- 200-day average
- $24.49
Price action over the past year
In 252 trading sessions since November 13, 2025, RCUS closed higher on 138 days (55%).
Its best day was March 2, 2026 (+17.53%) and its worst was October 21, 2026 (-19.58%).
The stock moved 10% or more in a single session 5 times.
Recent signals
RCUS news
-
Nov 6, 2026:
Wedbush Revises Best Ideas List After October Underperformance
-
Nov 4, 2026:
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
-
Nov 4, 2026:
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
-
Nov 2, 2026:
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
-
Oct 27, 2026:
Arcus Heads Into Third-Quarter Report With Stock Near Lows And Casdatafan Under Scrutiny
-
Oct 26, 2026:
Arcus Biosciences Announces New Employment Inducement Grants
-
Oct 24, 2026:
How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale
-
Oct 24, 2026:
Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses
About Arcus Biosciences, Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company which focuses on developing and commercializing cancer immunotherapies.
Similar stocks
Find more stocks like RCUS with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.